Analysts at HC Wainwright began coverage on shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.
A number of other research firms also recently commented on LABT. Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.
Check Out Our Latest Report on Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics Price Performance
Shares of LABT opened at $0.29 on Wednesday. Lakewood-Amedex Biotherapeutics has a one year low of $0.24 and a one year high of $98.20. The stock has a market capitalization of $678,294.00 and a PE ratio of -0.06. The stock’s 50 day moving average price is $1.51.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. Sell-side analysts predict that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current year.
Lakewood-Amedex Biotherapeutics Company Profile
Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.
The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.
Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.
Further Reading
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
